BeiGene Launches Third Celgene Cancer Drug in China

Beijing 's BeiGene has launched Vidaza® in China . Vidaza is a nucleoside metabolic inhibitor that is approved in China for patients with myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and chronic myelomonocyte leukemia (CMML). BeiGene acquired rights to Vidaza when it took over Celgene's China sales organization as part of the blockbuster $1.4 billion deal that gave Celgene global rights (ex-China) to BeiGene's PD-1 immunotherapy in 2017. More details.... Stock Symbols: (NSDQ: BGNE) (NSDQ: CELG) Share this with colleagues: // //